AletheiaHQ
Sign In
DIR-E8-87Y-NB6L/LVL 5·Leveraged OperationsHigh-leverage, capital-intensive cell operations. Requires fronted capital or established legal infrastructure. Examples: fronting $10k to lease warehouse space ahead of a known logistics fracture; forming a joint entity to secure and sub-license a dormant government patent for recurring royalties./80% confidence
Return to Directory

Monopolize SBIR Commercial Intelligence via FOIA-Enhanced Database

Organization
NSF/NIH SBIR program funding technical research without capturing commercial viability data
Sector
Biotech VCs seeking de-risked investments and specialized CROs hunting qualified leads
Location
Location unspecified

Source Reference

https://www.nsf.gov/awardsearch/showAward?AWD_ID=2604905

// Venture Capital// Biotech// Grant Writing// Data Scraping// Machine Learning & Modeling// Open-Source Intelligence// Health Policy & Regulation// Data Engineering & Pipelines

Executive Context

AICONIC BIOSCIENCES received $305K NSF SBIR Phase I funding for gene therapy research but faces a severe commercial execution gap between their research deliverables and the $100M+ required for FDA approval and market access. The SBIR program creates research capital without commercial infrastructure, generating multiple asymmetric opportunities around vendor procurement, commercial intelligence, and process IP capture.

Catalyst / Timing

NSF/NIH SBIR databases contain rich technical data but zero commercial intelligence, creating an information asymmetry between what funders know (technical merit) and what the market needs (commercial viability).

Projected Yield

$70K+ first quarter ($50K from VCs + $10K/month from CROs), scaling to $300K+ annually

Structural Friction

• Vulnerability: NSF/NIH SBIR databases contain rich technical data but zero commercial intelligence, creating an information asymmetry between what funders know (technical merit) and what the market needs (commercial viability). • Capital yield: $70K+ first quarter ($50K from VCs + $10K/month from CROs), scaling to $300K+ annually • Resource capture: Proprietary database of 200+ SBIR gene therapy companies with commercial gap analysis • Influence capture: Authority as the definitive source on SBIR-to-commercial transition intelligence • Sovereignty yield: Market position as the intelligence gateway between SBIR research and commercial capital • Required vectors: Vector: Data Scraping/Analysis, Vector: FOIA/Public Records, Vector: Biotech Commercial Intelligence, Vector: B2B Sales

Required Capabilities

  • Vector: Data Scraping/Analysis

    Primary executor: Phase 1: SBIR Intelligence Database Build: Scrape all NSF/NIH SBIR awards in gene therapy/AAV space from the past 3 year

  • Vector: FOIA/Public Records

    Supporting vector for: Monopolize SBIR Commercial Intelligence via FOIA-Enhanced Database

  • Vector: Biotech Commercial Intelligence

    Supporting vector for: Monopolize SBIR Commercial Intelligence via FOIA-Enhanced Database

  • Vector: B2B Sales

    Supporting vector for: Monopolize SBIR Commercial Intelligence via FOIA-Enhanced Database

Execution Protocol

Execution Protocol Locked

A one-time payment of $1799 unlocks the exact wedge, required assets, and step-by-step execution parameters yours forever, no subscription.

This report is synthesized intelligence, not verified instruction. Always confirm against the primary source before acting. Review the full legal disclaimer before proceeding.